Clinical Performance and Safety Comparison of Stay Safe Link® With Stay Safe® in Patient on CAPD (CAPD-3)

NCT ID: NCT03177031

Last Updated: 2019-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

472 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-13

Study Completion Date

2019-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This post-marketing study is undertaken to compare the clinical effectiveness and safety of two continuous ambulatory peritoneal dialysis produced by Fresenius Medical Care (FMC), i.e. Stay Safe® (STS) that is produced by a plant in Germany and Stay Safe Link® (SSL) that is produced in Malaysia. The study is an open labelled, randomised controlled trial where 434 patients in total will be randomised to either STS or SSL in a 1:1 ratio.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Continuous Ambulatory Peritoneal Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stay Safe (STS)

CAPD system produced by Fresenius Medical Care in Germany

Group Type ACTIVE_COMPARATOR

Stay Safe (STS)

Intervention Type DEVICE

CAPD system produce in Germany by Fresenius Medical Care

Stay Safe Link (SSL)

CAPD system produced by Fresenius Medical Care in Malaysia

Group Type EXPERIMENTAL

Stay Safe Link (SSL)

Intervention Type DEVICE

CAPD system produced in Malaysia by Fresenius Medical Care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stay Safe Link (SSL)

CAPD system produced in Malaysia by Fresenius Medical Care

Intervention Type DEVICE

Stay Safe (STS)

CAPD system produce in Germany by Fresenius Medical Care

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age or above
2. End stage kidney failure receiving Stay Safe® PD system for at least 4 weeks
3. Written informed consent

Exclusion Criteria

1. Requirement for 2.5L exchanges
2. Requirement for Stay Safe Balance®
3. PD-related infection (peritonitis, exit site or tunnel tract infection) in the preceding 8 weeks or during conversion
4. Malfunctioning of PD catheter
5. Planned transfer to automated peritoneal dialysis, haemodialysis or transplant within 90 days
6. Pregnancy
7. Any condition that compromises the integrity of the abdominal wall, abdominal surface, or intra-abdominal cavity, such as documented loss of peritoneal function
8. History of active alcohol or substance abuse in the previous 6 months
9. Other medical condition which, in the investigator's judgement, may be associated with increased risk to the subject or may interfere with study assessments or outcomes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Penang Hospital, Malaysia

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Loke Meng Ong

Role: PRINCIPAL_INVESTIGATOR

Clinical Research Centre, Penang General Hospital, Malaysia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Centre, Penang Hospital

George Town, Pulau Pinang, Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

References

Explore related publications, articles, or registry entries linked to this study.

Mak WY, Ong LM, Goh BL, Bavanandan S, Mushahar L, Leong CT, Hooi LS. Protocol for a randomised, open-label, parallel group, multicentre controlled study to evaluate the clinical performance and safety of Stay Safe Link compared with Stay Safe in patients with end-stage kidney disease on continuous ambulatory peritoneal dialysis. BMJ Open. 2019 Mar 8;9(3):e024589. doi: 10.1136/bmjopen-2018-024589.

Reference Type DERIVED
PMID: 30852538 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HPP/CTP/PD/003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Xeltis Hemodialysis Access Graft: aXess Pivotal Study
NCT05473299 ACTIVE_NOT_RECRUITING NA
Evaluation of STARgraft-3 for Hemodialysis
NCT05729620 ACTIVE_NOT_RECRUITING NA
A Clinical Trial of IntensiVE Dialysis
NCT00649298 COMPLETED PHASE4